Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

AI Stock Picker
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Resources

Blog
Earnings
Tutorial
Partner Program

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CGON
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
CGON
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

CGON Similar Chart Price Prediction

The price of CGON is predicted to go up -2.51%, based on the high correlation periods with PRK. The similarity of these two price pattern on the periods is 91.59%.

stocks logo

CGON

stocks logo

PRK

Down: -2.51%Similarity: 91.59%

CGON Revenue Forecast

CGON EPS Forecast

CGON FAQs

What is bull’s view on CGON?

CGON stock is currently trading at $30.03, with a bullish price target of $75 set by HC Wainwright analysts, implying a 150% upside. The optimism stems from strong Phase 3 results for its bladder cancer therapy, Cretostimogene, which achieved a 74.5% complete response rate and durable efficacy over 24 months. Additionally, CGON's robust cash position supports its pipeline development, making it a promising high-risk, high-reward investment.

What is bear's view on CGON?

CGON stock closed at $30.07 on January 31, 2025, down 0.27% for the day. Bears argue that CGON faces limited near-term impact from its CREST study due to ongoing BCG shortages and hesitancy among urologists to adopt immune-oncology therapies. Additionally, the stock has declined significantly from its 2024 peak of $50.23, reflecting concerns over its reliance on a single asset, cretostimogene.

What is CGON revenue forecast for next quarter？

The market consensus for CGON's revenue in the upcoming quarter is projected to be approximately $154.16K USD.

CGON VS S&P500

Ask Intellectia about CGON

CGON Analyst's Forecast

Tyler Van Buren

TD Cowen

Strong Buy

2025-01-07

Price Target

n/a

Downside

0%

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology with a Buy rating and no price target. The firm says cretostimogene is differentiated by its "superior" efficacy and safety to standard of care in BCG-unresponsive, non-muscle invasive bladder cancer, with intravesical administration that is already deployed in practices. TD expects the management team to successfully launch cretostimogene in 2026.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
AI Stock PickerFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisStock Chart PatternsEarnings TradingAI Screener
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free

Hot Stocks

stocks logo

NSIT

Insight Enterprises Inc

$160.87
-3.09%
stocks logo

MGY

Magnolia Oil & Gas Corp

$24.04
-2.28%
stocks logo

INGM

Ingram Micro Holding Corp

$23.31
-1.56%
stocks logo

FFIN

First Financial Bankshares Inc

$36.83
-1.29%
stocks logo

IESC

IES Holdings Inc

$193.355
-2.82%
stocks logo

VLY

Valley National Bancorp

$9.535
-3.10%
stocks logo

FRSH

Freshworks Inc

$17.31
-4.47%
stocks logo

MAIN

Main Street Capital Corp

$62.27
-0.75%
stocks logo

SNDR

Schneider National Inc

$27.28
0.78%
stocks logo

CUZ

Cousins Properties Inc

$30.09
-0.86%